

PRESS RELEASE

Heidelberg Pharma to Present First Efficacy Data on HDP-101 and Data from Proprietary ADC Technology Platform at AACR Meeting 2024

Ladenburg, Germany, 6 March 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs) will be presenting first efficacy data on its Phase I clinical trial with ATAC candidate HDP-101 as well as preclinical data on other drug candidates from its proprietary ADC technology platform at the American Association for Cancer Research (AACR) Annual Meeting, being held in San Diego, California on the 5 - 10 April 2024.

Details of the conference and poster presentations are as follow:

Late Breaking Research: Poster: Multimeric linker-exatecan-based ADC targeting Guanylyl cyclase C (GCC) as novel therapeutic modality for treatment of colorectal cancer

Abstract number: LB059, Section 53
Session: Late-Breaking Research: Experimental and Molecular Therapeutics 1
Presentation time: 7 April 2024, 1:30 pm – 5:00 pm PDT
Speaker: Dr. Sarah-Jane Neuberth
Link to abstract: Late-breaking abstracts are available on 5 April 2024.

Clinical Trials 1: Poster: The anti-BCMA antibody-drug conjugate HDP-101 with a novel amanitin payload shows promising initial first in human results in relapsed multiple myeloma

Abstract number: CT067, Section 48
Session: Phase I Clinical Trials 1
Presentation time: 8 April 2024, 9:00 am - 12:30 pm PDT
Speaker: Dr. András Strassz
Link to abstract: Clinical-trials abstracts are available on 5 April 2024.

Poster: HDP-102 – a CD37-targeting Amanitin-based-ADC for the treatment of NHL – non-clinical data package

Abstract number: 1865, Section 22
Session: Antibody-Based Technologies and New Inhibitors
Presentation time: 8 April 2024, 9:00 am - 12:30 pm PDT
Speaker: Dr. Sarah-Jane Neuberth
Link to abstract: <https://www.abstractsonline.com/pp8/#!/20272/presentation/8116>

The poster presentation details preclinical data on ATAC candidate HDP-102, an Amanitin-based-ADC that is directed against the target molecule CD37. CD37 is found exclusively on immune cells, primarily B cells, and is overexpressed in malignant B-cell diseases such as Non-Hodgkin's lymphoma (NHL).

HDP-102 has demonstrated excellent anti-tumor efficacy in *in-Vivo*-studies after a single administration and initial preclinical studies display good tolerability, indicating HDP-102 as a potential new treatment option for patients with NHL.

Poster: Liver toxicity of Amanitin-based Antibody drug conjugates (ATACs) is caused by unspecific uptake of the ATAC into liver cells

Abstract number: 7183, Section 24
Session: Pharmacology and Pharmacogenetics
Presentation time: 10 April 2024, 9:00 am - 12:30 pm PDT
Speaker: Dr. Christian Orlik
Link to abstract: <https://www.abstractsonline.com/pp8/#!/20272/presentation/8047>

The use of antibody-drug conjugates (ADCs), which combine high efficacy of cytotoxins with the specificity of antibodies, is still often limited by side effects. These include the binding of the ADCs independently of the target antigen (off-target toxicity mechanisms), which is responsible, for example, for the premature release of the transported cytotoxins.

The study details, the off-target toxicity mechanisms of ADCs that use amatoxins (RNA polymerase II inhibitors) as payload, so-called ATACs, were deciphered. The data reveals that liver toxicity is caused by non-specific uptake of the ATACs into liver cells. The substitution of two amino acids of the antibody (LALA mutation) that are responsible for the unspecific binding of the ATAC reduces the off-target toxicity. This significantly increases the tolerability of ATACs while leaving the antitumor efficacy unaffected, resulting in an improved therapeutic window of ATACs.

About Heidelberg Pharma

Heidelberg Pharma is an oncology specialist and the first company to develop the toxin Amanitin into cancer therapies using its proprietary ATAC technology and to advance the biological mode of action of the toxin as a novel therapeutic principle. The proprietary technology platform is being applied to develop the company's own therapeutic ATACs as well as in third-party collaborations.

The proprietary lead candidate HDP-101 is a BCMA-ATAC in clinical development for multiple myeloma. Further ATAC candidates are being developed against different targets such as CD37, PSMA or GCC each in the indications non-Hodgkin's lymphoma, metastatic castration-resistant prostate cancer or gastrointestinal tumors such as colorectal cancer.

Heidelberg Pharma AG is based in Ladenburg, Germany, and is listed on the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol HPHA. More information is available at www.heidelberg-pharma.com.

ATAC® is a registered trademark of Heidelberg Pharma Research GmbH in the EU and the USA.

Contact

Heidelberg Pharma AG

Sylvia Wimmer

Director Corporate Communications

Tel.: +49 89 41 31 38-29

E-Mail: investors@hdpharma.com

Gregor-Mendel-Str. 22, 68526 Ladenburg

IR/PR-Support

MC Services AG

Katja Arnold (CIRO)

Managing Director & Partner

Tel.: +49 89 210 228-40

E-Mail: katja.arnold@mc-services.eu

IR/PR-Support

Optimum Strategic Communications

Mary Clark, Zoe Bolt, Katie Flint

Tel: +44 20 3882 9621

Email: HeidelbergPharma@optimumcomms.com

This communication contains certain forward-looking statements relating to the Company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "will", "should", "future", "potential" or similar expressions or by a general discussion of the Company's strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial condition, performance, or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.